These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 22555244)
1. Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy. Kimura T; Okamoto K; Miyamoto H; Kimura M; Kitamura S; Takenaka H; Muguruma N; Okahisa T; Aoyagi E; Kajimoto M; Tsuji Y; Kogawa T; Tsuji A; Takayama T Oncology; 2012; 82(5):298-304. PubMed ID: 22555244 [TBL] [Abstract][Full Text] [Related]
2. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
3. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556 [TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
5. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
6. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573 [TBL] [Abstract][Full Text] [Related]
7. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604 [TBL] [Abstract][Full Text] [Related]
8. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677 [TBL] [Abstract][Full Text] [Related]
9. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608 [TBL] [Abstract][Full Text] [Related]
10. Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation. Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Sugiyama M; Watanabe T Oncol Rep; 2014 Jul; 32(1):57-64. PubMed ID: 24839940 [TBL] [Abstract][Full Text] [Related]
11. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213 [TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366 [TBL] [Abstract][Full Text] [Related]
13. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097 [TBL] [Abstract][Full Text] [Related]
14. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037 [TBL] [Abstract][Full Text] [Related]
15. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774 [TBL] [Abstract][Full Text] [Related]
16. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Tol J; Punt CJ Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983 [TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related]
19. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860 [TBL] [Abstract][Full Text] [Related]
20. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Baynes RD; Gansert J Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]